Navigation Links
Kemwell Appoints Dr. Ninad Deshpanday to Head Global R&D

BANGALORE, February 15, 2013 /PRNewswire/ --

Kemwell Biopharma Pvt. Ltd, a global pharmaceutical contract development and manufacturing company, announced that it has appointed Dr. Ninad Deshpanday as President of Research and Development.

Anurag Bagaria , Chairman and Managing Director of Kemwell said, "Dr. Deshpanday brings a unique combination of leadership skills and technical expertise in pharmaceutical development, as well as excellent business development skills with a very strong network of customers in the US, Europe and Asia. He will spearhead the R&D business for Kemwell as we continue to grow the geographical footprint and strategically position Kemwell into a leading Global Contract Services Provider."

Dr. Deshpanday has over 22 years' experience of diverse international experience in the pharmaceutical industry (US + India). This includes pharmaceutical development activities for NDAs, specialty drug delivery based 505(b)(2) products, including Oral and Transdermal, and complex Generic products, with several F2Fs and PIVs. He also has rich experience in Technical and Business Development

Prior to joining Kemwell, he was President of Pharmaceutical R&D at Lupin, in Pune, India since Nov. 2007, with leadership responsibilities for formulations, analytical, and BA/BE activities. Before joining Lupin, Dr. Deshpanday was Vice President of Business Development at AAIPharma in RTP, NC, with responsibilities for sales and marketing activities for their CM&C functions; Vice President for Drug Product Development for Synta Pharmaceuticals, with responsibilities for all CM&C activities; and Technical Business Director for the Pharmaceutics division of Cardinal Health. Dr. Deshpanday earned his Doctorate in Pharmaceutics from the University of S. Carolina in 1990, and has an M. Pharm. and B. Pharm. from LM College of Pharmacy in Ahmedabad, India.

About Kemwell Biopharma Pvt. Ltd.

Kemwell Biopharma Pvt. Ltd, headquartered in Bangalore, India is a pure-play global contract development and manufacturing company. The company manufactures and develops pharmaceuticals for some of the world's top pharmaceutical companies, including GlaxoSmithKline, Bayer, Novartis and Pfizer. Kemwell is one of India's largest contract manufacturers of pharmaceuticals with over 30 years' experience. The company employs more than 1000 employees worldwide and has seven production facilities, five in India and two in Sweden. Kemwell is an approved pharmaceutical manufacturer in over 80 countries including the American, European, Japanese and Indian markets. Read more about Kemwell on

Primary Media Contact: Karan Bagaria ,, 91-80-39286200

Secondary Media Contact: Bhaskar Viswanathan ,, 91-80-39286200

SOURCE Kemwell Biopharma Pvt Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Avantium Appoints Jonathan Wolfson to its Supervisory Board
2. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
3. PCI Appoints Jose Solorio-Ruiz, MBA, Manager of West Coast Operations
4. Advanced Cell Diagnostics Appoints Evangeline Gonzalez as Chief Commercial Officer
5. California Healthcare Institute Appoints Allergan CEO Chairman of the Board, Elects New Board Members
6. uniQure Appoints Philip Astley-Sparke President US
7. HealthEconomics.Com Appoints New Director of Information Technology and Operations
8. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
9. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
10. Lakewood-Amedex Inc. Appoints Marie E. Knight To Its Board Of Directors
11. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
Post Your Comments:
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Halozyme Therapeutics, Inc. ... Healthcare Conference in New York on Wednesday, ... Helen Torley , president and CEO, will provide a corporate ... New York at 1:00 p.m. ET/10:00 a.m. PT ... and investor relations, will provide a corporate overview. --> ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/29/2015)... , October 29, 2015 ... biometric authentication company focused on the growing mobile ... wallet announces that StackCommerce, a leading marketplace to ... featuring the Wocket® smart wallet on StackSocial for ... ) ("NXT-ID" or the "Company"), a biometric authentication ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
Breaking Biology News(10 mins):